Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
This protein contains a furin-like convertase cleavage site, 355-RQYR-358, and will be partially processed into N and C-terminal fragment with calculated MW of 38.1 kDa and 24.6 kDa respectively. The protein migrates as 30 kDa, 40 kDa and 65-80 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human Glypican 3, His Tag, premium grade on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
The purity of Human Glypican 3, His Tag, premium grade (Cat. No. GP3-H52H4) is more than 90% and the molecular weight of this protein is around 61-75 kDa verified by SEC-MALS.
2e5 of anti-GPC3 CAR-293 cells were stained with 100 μL of 3 μg/mL of Human Glypican 3, His Tag, premium grade (Cat. No. GP3-H52H4) and negative control protein respectively, washed and then followed by FITC anti-his tag antibody and analyzed with FACS (Routinely tested).
Immobilized Human Glypican 3, His Tag, premium grade (Cat. No. GP3-H52H4) at 0.5 μg/mL (100 μL/well) can bind Anti-Human GPC3 MAb with a linear range of 0.1-12.5 ng/mL (QC tested).
Anti-human GPC3 MAb (chimeric mouse-human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Glypican 3, His Tag, premium grade (Cat. No. GP3-H52H4) with an affinity constant of 1.33 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Loaded Anti-Human GPC3 MAb (chimeric mouse-human IgG1) on AHC Biosensor, can bind Human Glypican 3, His Tag, premium grade (Cat. No. GP3-H52H4) with an affinity constant of 1.48 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
GPC-3298306 | GPC-3298306 | Phase 2 Clinical | National Cancer Center Of Japan | Ovarian Neoplasms; Carcinoma, Hepatocellular | Details |
BOS-342 | PRS-342; BOS-342; PRS-342/BOS-342 | Phase 2 Clinical | Pieris Pharmaceuticals | Solid tumours; Carcinoma, Hepatocellular | Details |
BOXR-1030 | BOXR-1030 | Phase 2 Clinical | Unum Therapeutics Inc | Liver Neoplasms; Carcinoma, Merkel Cell; Lung Neoplasms; Carcinoma, Squamous Cell; Liposarcoma, Myxoid; Carcinoma, Hepatocellular | Details |
AZD-9793 | AZD9793; AZD-9793 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Hepatocellular | Details |
CAR-T Cell Therapy Targeting GPC3(Pla General Hospital) | Phase 2 Clinical | Pla General Hospital | Carcinoma, Hepatocellular | Details | |
MRG-006A | MRG-006A; MRG-006; MRG006A | Phase 2 Clinical | Lepu Biopharma Co Ltd, Shanghai Miracogen Inc | Solid tumours; Neoplasms; Carcinoma, Hepatocellular | Details |
C-CAR031 CAR T-cell therapy (AbelZeta) | C-CAR031 | Phase 2 Clinical | Cellular Biomedicine (Shanghai) Co Ltd | Carcinoma, Hepatocellular | Details |
NY-303 | NY-303 | Phase 2 Clinical | NAYA Biosciences Inc | Solid tumours; Carcinoma, Hepatocellular | Details |
AZD-5851 | AZD-5851; AZD5851 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Hepatocellular | Details |
SAR-444200 | SAR-444200 | Phase 2 Clinical | Sanofi | Solid tumours; Neoplasms | Details |
CMD-011 | CMD-011 | Phase 2 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
CAR-GPC3 T-cell (Drum Tower Hospital) | Phase 2 Clinical | Nanjing Drum Tower Hospital | Carcinoma, Hepatocellular | Details | |
GPC3 CAR-T therapy (Hrain Biotechnology) | Phase 2 Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Hepatocellular | Details | |
CM-350 | CM-350 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Solid tumours | Details |
GPC3-CAR-T cell therapy(Origincell Medical Technology) | Ori-CAR-001; Ori-C101(OriCell) | Phase 2 Clinical | OriCell Therapeutics Co Ltd | Carcinoma, Hepatocellular | Details |
ECT-204 | JWATM-204; ECT-204 | Phase 2 Clinical | Eureka Therapeutics Inc, Jw Therapeutics (Shanghai) Co Ltd | Liver Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
Codrituzumab | GC-33; RG-7686; RO-5137382 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
GPC3-T2 CAR-T cell therapy (The Second Affiliated Hospital of Guangzhou Medical University) | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details | |
GLYCAR T cell therapy (Baylor College of Medicine) | GLYCAR | Phase 1 Clinical | Baylor College Of Medicine | Rhabdomyosarcoma; Liver Neoplasms; Hepatoblastoma; Rhabdoid Tumor; Wilms Tumor; Liposarcoma; Carcinoma, Hepatocellular; Endodermal Sinus Tumor | Details |
Anti-GPC3 CAR T-cell therapy (Carbiogene Therapeutics) | CBG166; CBG-166 | Phase 1 Clinical | Nanjing University, Carbiogene Therapeutics Co Ltd | Carcinoma, Hepatocellular | Details |
GPC3-CAR-T cell therapy | CSG-GPC-3; CAR-GPC3 T-cell; GPC3-CAR/CSG-GPC3; anti-GPC-3 CAR T; KJgpc3-001; CT-011 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Solid tumours; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details |
Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Zhaotai Yongren Biotech/Guangdong Zhaotai Invivo Biomedicine) | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech Co Ltd, Guangdong Zhaotai Invivo Biomedicine Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details | |
GPC3-T2-CAR-T | GPC3-T2-CAR-T | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Carcinoma, Hepatocellular | Details |
EU-307 | EU307 | Phase 1 Clinical | Eutilex | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
Ori-CAR-002 | Ori-CAR-002; GPC3-CAR-Ori2 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Multiple Myeloma | Details |
SENTI-301 | SENTI-301; SENTI-301A; SN301A | Phase 1 Clinical | Senti Biosciences Inc | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
MT-303(Myeloid) | MT-303(Myeloid) | Phase 1 Clinical | Myeloid Therapeutics Inc | Carcinoma, Hepatocellular | Details |
68Ga-aGPC3-scFv/Fab | 68Ga-aGPC3-scFv/Fab | Phase 1 Clinical | Wuhan Union Hospital | Liver Neoplasms | Details |
BGB-B2033 | BGB-B2033; BGB-B-2033 | Phase 1 Clinical | Beigene Guangzhou Biologics Manufacturing Co Ltd | Solid tumours; Stomach Neoplasms; Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
BC-2027 | BC2027; BC-2027 | Phase 1 Clinical | Wuxi BioCity | Liver Neoplasms; Solid tumours | Details |
JMT-106 | JMT106; JMT-106 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Solid tumours | Details |
AST-201 (Aptamer Sciences) | AST-201(Aptamer Sciences) | Phase 1 Clinical | Aptamer Sciences Inc | Liver Neoplasms; Solid tumours; Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
GPC3/Mesothelin-CAR-γδT Cells therapy(Second Affiliated Hospital Of Guangzhou Medical University) | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Solid tumours; Liver Neoplasms; Pancreatic Neoplasms; Mesothelioma; Lung Neoplasms | Details | |
RYZ-801 | RYZ-801(225Ac); RYZ-801; ABZ-706; 225Ac-GPC3 | Phase 1 Clinical | PeptiDream Inc, RayzeBio Inc | Carcinoma, Hepatocellular | Details |
NWRD-06 | NWRD-06; NWRD06 | Phase 1 Clinical | Newish Technology (Beijing) Co Ltd | Carcinoma, Hepatocellular | Details |
GPC3-targeted CAR-T (Peking University) | Phase 1 Clinical | Peking University | Carcinoma, Hepatocellular | Details | |
CAR (hYP7)-T cells (National Cancer Institute) | Phase 1 Clinical | National Cancer Institute | Carcinoma, Hepatocellular | Details | |
TC-CAR-031 | C-CAR-031; TC-CAR-031; TC-CAR031; C-CAR031 | Phase 1 Clinical | Zhejiang University, Cellular Biomedicine Group Inc | Carcinoma, Hepatocellular | Details |
IM-83 CAR-T cell therapy | IM-83; IM83 | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Liver Neoplasms; Neoplasms; Osteosarcoma; Carcinoma, Hepatocellular | Details |
CT-017 | CT-017 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Carcinoma, Hepatocellular | Details |
JWATM-214 | JWATM-214; JWATM214 | Phase 1 Clinical | Suzhou Yaomingjunuo Biotechnology Co Ltd | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
TH-012(Bangentai Biomedical) | TH-012 | Phase 1 Clinical | Shandong Bangentai Biomedical Tech Group Co Ltd | Stomach Neoplasms; Pancreatic Neoplasms | Details |
B010-A | B010-A | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Carcinoma, Hepatocellular | Details |
CT-0180 | CT-0180 | Phase 1 Clinical | CARsgen Therapeutics Holdings Ltd | Carcinoma, Hepatocellular | Details |
ERY-974 | ERY-974 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
TAK-102 | TAK-102; NIB-102 | Phase 1 Clinical | Noile-Immune Biotech Inc | Solid tumours | Details |
HRAIN-011 | HRAIN-011 | Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Hepatocellular | Details |
Anti-GPC3-IRDye800CW | Clinical | Chinese Academy Of Sciences | Details |
This web search service is supported by Google Inc.